Abstract
A growing wealth of evidence indicates that the key pathological event in Alzheimers disease is the conversion of the normal soluble amyloid-β peptide into β-sheet-rich oligomeric structures which have a neurotoxic activity and ability to form insoluble amyloid deposits that accumulate in the brain. b-sheet breakers constitute a new class of drugs that are designed to specifically bind amyloid-β peptide and block and / or reverse this abnormal conformational change. In this article we review this approach, describe diverse compounds reported to have this activity and summarize the data supporting the view that b-sheet breakers could be serious candidates to combat this devastating disease.
Keywords: alzheimer disease, amyloid, therapy
Current Drug Targets
Title: β-Sheet Breakers for Alzheimers Disease Therapy
Volume: 5 Issue: 6
Author(s): Bieler S. and Soto C.
Affiliation:
Keywords: alzheimer disease, amyloid, therapy
Abstract: A growing wealth of evidence indicates that the key pathological event in Alzheimers disease is the conversion of the normal soluble amyloid-β peptide into β-sheet-rich oligomeric structures which have a neurotoxic activity and ability to form insoluble amyloid deposits that accumulate in the brain. b-sheet breakers constitute a new class of drugs that are designed to specifically bind amyloid-β peptide and block and / or reverse this abnormal conformational change. In this article we review this approach, describe diverse compounds reported to have this activity and summarize the data supporting the view that b-sheet breakers could be serious candidates to combat this devastating disease.
Export Options
About this article
Cite this article as:
S. Bieler and C. Soto, β-Sheet Breakers for Alzheimers Disease Therapy, Current Drug Targets 2004; 5 (6) . https://dx.doi.org/10.2174/1389450043345290
DOI https://dx.doi.org/10.2174/1389450043345290 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies
Current Bioactive Compounds Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Current Pharmaceutical Design Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies The Diagnostic Value of CSF Amyloid-β<sub>43</sub> in Differentiation of Dementia Syndromes
Current Alzheimer Research Anti-obesity Effects of Some Plant Extracts in Rats Fed with High-Fat Diet
The Natural Products Journal Platelet Alpha- and Beta- Secretase Activities are not Significantly Affected by Dementia or Mild Cognitive Impairment in Swedish Patients
Current Alzheimer Research The Proteasome in Health and Disease
Current Pharmaceutical Design Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry Minocycline and Cytoprotection: Shedding New Light on a Shadowy Controversy
Current Drug Delivery The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer
Reviews on Recent Clinical Trials Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets The Neurotrophins and Their Role in Alzheimers Disease
Current Neuropharmacology Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders
Current Pharmaceutical Design